Bottom line
GTHRX vs JEHSX: the short answer
GTHRX (INVESCO Health Care Fund) and JEHSX (Health Sciences Trust) are both mutual funds.
But JEHSX is far broader, holding 173 positions to 82 for GTHRX, so beyond the top names it adds exposure GTHRX doesn't have.
JEHSX is cheaper at 1.04% vs 1.32% — a difference of $28 a year per $10,000 invested.
Over five years, JEHSX returned +4.2% a year vs +3.5% for GTHRX.
Updated Nov 19, 2026
GTHRX vs JEHSX side by side
| GTHRX | JEHSX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Invesco | John Hancock |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 1.32% | 1.04% |
| Annual cost per $10k | $132 | $104 |
| 10-yr cost on $10k (prospectus) | $1,590 | $1,282 |
| Max front load | 0% | — |
| 12b-1 fee | 0.5% | 0.05% |
| 1-yr return | +15.2% | +19.5% |
| 5-yr return (annualized) | +3.5% | +4.2% |
| 10-yr return (annualized) | +6.1% | +8.7% |
| Best quarter | +19.6% | +23.6% |
| Worst quarter | −16.5% | −16.1% |
| Net assets (fund) | $1.2B | $251.3M |
| Number of holdings | 82 | 173 |
| Portfolio turnover | 59% | 68% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | GTHRX | JEHSX | Difference |
|---|---|---|---|
| 2024 | +4.0% | +1.8% | +2.2% |
| 2023 | +3.1% | +4.3% | −1.2% |
| 2022 | −13.5% | −13.1% | −0.4% |
| 2021 | +12.2% | +11.2% | +1.0% |
| 2020 | +14.5% | +27.2% | −12.7% |
| 2019 | +32.0% | +28.7% | +3.3% |
| 2018 | +0.5% | +0.7% | −0.2% |
| 2017 | +15.5% | +27.5% | −12.1% |
| 2016 | −11.7% | −10.6% | −1.1% |
Source: Fund prospectus bar charts
Holdings overlap
12 of GTHRX's top 25 holdings also appear in JEHSX's top 25.
| Holding | GTHRX | JEHSX |
|---|---|---|
| Eli Lilly and Co. | 10.59% | 14.30% |
| Johnson & Johnson | 6.76% | 6.33% |
| UnitedHealth Group Inc. | 6.17% | 5.95% |
| Merck & Co., Inc. | 4.59% | 4.21% |
| AbbVie Inc. | 4.03% | 5.28% |
| Gilead Sciences, Inc. | 3.63% | 2.95% |
| CVS Health Corp. | 2.52% | 0.98% |
| BrightSpring Health Services, Inc. | 2.20% | 0.88% |
| Cardinal Health, Inc. | 2.10% | 1.09% |
| Guardant Health, Inc. | 2.04% | 1.28% |
| Vertex Pharmaceuticals Inc. | 2.01% | 2.38% |
| Thermo Fisher Scientific Inc. | 1.55% | 2.67% |
Source: SEC Form N-PORT
GTHRX top 10
- Eli Lilly and Co. — 10.59%
- Johnson & Johnson — 6.76%
- UnitedHealth Group Inc. — 6.17%
- Invesco Private Prime Fund — 4.67%
- Merck & Co., Inc. — 4.59%
- AbbVie Inc. — 4.03%
- Gilead Sciences, Inc. — 3.63%
- argenx SE — 3.24%
- CVS Health Corp. — 2.52%
- Welltower Inc. — 2.34%
JEHSX top 10
- Eli Lilly and Company — 14.30%
- Johnson and Johnson — 6.33%
- UnitedHealth Group Incorporated — 5.95%
- AbbVie Inc. — 5.28%
- Merck and Co. Inc. — 4.21%
- Gilead Sciences Inc. — 2.95%
- Thermo Fisher Scientific Inc. — 2.67%
- Vertex Pharmaceuticals Incorporated — 2.38%
- Bristol-Myers Squibb Company — 2.22%
- Abbott Laboratories — 2.00%
FAQ
What is the difference between GTHRX and JEHSX?
Which is cheaper, GTHRX or JEHSX?
Should I own both GTHRX and JEHSX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.